Li Bin, Li Weihong, Li Xiaoli, Zhou Hong
Department of Pharmacology, College of Pharmacy, Third Military Medical University, Chongqing 400038. China.
Assisted Reproductive Center, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016. China.
Curr Pharm Des. 2017;23(8):1216-1227. doi: 10.2174/1381612822666161230142931.
Over the past two decades, the viewpoint of atherosclerosis has been replaced gradually by a lipiddriven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment of atherosclerosis is focused on limiting its risk factors, such as hyperlipidemia or hypertension. However, treatment targeting the inflammatory nature of atherosclerosis is still very limited and deserves further attention to fight atherosclerosis successfully. Here, we review the current development of inflammation and atherosclerosis to discuss novel insights and potential targets in atherosclerosis, and to address drug discovery based on anti-inflammatory strategy in atherosclerotic disease.
在过去二十年中，动脉粥样硬化的观点已逐渐被一种由脂质驱动的、慢性的、低度炎症性的动脉壁疾病所取代。目前动脉粥样硬化的治疗重点在于限制其危险因素，如高脂血症或高血压。然而，针对动脉粥样硬化炎症本质的治疗仍然非常有限，值得进一步关注以成功对抗动脉粥样硬化。在此，我们综述炎症与动脉粥样硬化的当前进展，以讨论动脉粥样硬化的新见解和潜在靶点，并探讨基于抗炎策略的动脉粥样硬化疾病药物研发。
